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ABSTRACT 
Background and Purpose: Exposure to nanoparticulate pollution has been implicated in 
platelet-driven thrombotic events such as myocardial infarction. Inflammation and 
impairment of nitric oxide (NO) bioavailability have been proposed as potential causative 
mechanisms. It is unclear, however, whether airways exposure to combustion-derived 
nanoparticles such as diesel exhaust particles (DEP) or carbon black (CB) can augment 
platelet aggregation in vivo and the underlying mechanisms remain undefined. We aimed to 
investigate the impact of acute lung exposure to DEP and CB upon platelet activation and the 
associated role of inflammation and endothelial-derived NO. 
Experimental Approach: DEP and CB were intratracheally instilled into wild-type (WT) and 
eNOS
-/-
 mice and platelet aggregation was assessed in vivo using an established model of 
radiolabelled platelet thromboembolism. The underlying mechanisms were investigated by 
measuring inflammatory markers, NO metabolites and light transmission aggregometry. 
Key Results: Platelet aggregation in vivo was significantly enhanced in WT and eNOS
-/-
 mice 
following acute airways exposure to DEP but not CB. CB exposure but not DEP, was 
associated with significant increases in pulmonary neutrophils and IL-6 levels in the 
bronchoalveolar lavage fluid and plasma of WT mice. Neither DEP nor CB affected plasma 
nitrate/nitrite concentration and DEP-induced human platelet aggregation was inhibited by an 
NO donor. 
Conclusions and Implications: Pulmonary exposure to DEP and subsequent platelet 
activation may be implicated in the reported increased cardiovascular risk associated with 
exposure to airborne pollution independent of its impact on inflammation or NO 
bioavailability.  
 
Abbrieviations: BALF: broncheoavleolar lavage fluid; CB: carbon black; DEP: diesel 
exhaust particles; eNOS: endothelial nitric oxide synthase; eNOS
-/-
: endothelial nitric oxide 
synthase knock-out mice; MI: myocardial infarction; NO: nitric oxide; PM: particulate 
matter; PMN: polymorphonuclear leukocyte 
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INTRODUCTION 
Exposure to ambient particulate matter (PM) is associated with thrombotic events such as 
myocardial infarction (MI) and stroke (Peters, Dockery, Muller & Mittleman, 2001). The PM 
0.1 fraction of air pollution, which includes diesel exhaust particles (DEP) and carbon black 
(CB) and is principally combustion generated from vehicle emissions, is strongly implicated 
as a causative risk factor for these cardiovascular events (Andersen, Olsen, Andersen, Loft, 
Ketzel & Raaschou-Nielsen, 2010).  Platelet activation and aggregation are important drivers 
of the thrombotic events associated with exposure to PM 0.1 (Lucking et al., 2008; Nemmar, 
Hoet, Dinsdale, Vermylen, Hoylaerts & Nemery, 2003; Solomon et al., 2013). 
Lung exposure to DEP has been shown to enhance experimental thrombosis and platelet 
activation in both animal models (Nemmar, Hoet, Dinsdale, Vermylen, Hoylaerts & Nemery, 
2003; Nemmar, Nemery, Hoet, Vermylen & Hoylaerts, 2003) and man (Lucking et al., 2008). 
Exposure to both DEP and CB has been associated with inflammation (Gilmour et al., 2004; 
Lucking et al., 2008; Nemmar, Hoet, Dinsdale, Vermylen, Hoylaerts & Nemery, 2003; 
Nemmar, Nemery, Hoet, Vermylen & Hoylaerts, 2003) and initiation of pulmonary and 
systemic inflammation has been proposed as a mechanism by which PM 0.1 inhalation may 
promote platelet aggregation and thrombosis (Mills et al., 2005; Oberdorster, Ferin, Gelein, 
Soderholm & Finkelstein, 1992). Interleukin-6 (IL-6) has been particularly associated with 
diesel exhaust (DE) or DEP exposure in both rodents (Conklin, Kong & Committee, 2015; 
Robertson et al., 2012) and humans (Krishnan et al., 2013). In addition, leukocyte infiltration 
in the lungs is widely reported following exposure to DEP (Nemmar, Nemery, Hoet, 
Vermylen & Hoylaerts, 2003; Oberdorster, Ferin, Gelein, Soderholm & Finkelstein, 1992; 
Robertson et al., 2012; Xu et al., 2013). In contrast, DEP was able to accelerate thrombosis in 
rats without evidence of pulmonary or systemic inflammation (Tabor et al., 2016) so that the 
role of inflammation in driving DEP-associated cardiovascular risk remains unclear. 
As an alternative to the inflammation mechanism, it has been reported that nanoscale 
materials can translocate across the pulmonary epithelial barrier and enter the circulation. 
Thus, nanoparticles may interact directly with blood components including platelets 
(Kreyling et al., 2009; Nemmar, Vanbilloen, Hoylaerts, Hoet, Verbruggen & Nemery, 2001; 
Oberdorster et al., 2002). Previous work by us showed that DEP can physically interact with 
isolated platelets leading to activation and aggregation as well as enhancement of aggregation 
at lower concentrations (Solomon et al., 2013). Furthermore, systemic administration of DEP 
by the intravenous route, to mimic a scenario in which PM 0.1 traversed the lung epithelium, 
caused enhanced platelet aggregation in vivo (Solomon et al., 2013) and thrombogenesis 
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(Tabor et al., 2016). Binding of DEP to glycoprotein VI (GPVI) and/or C-type lectin-like 
receptor-2 (CLEC-2) has been suggested to be an underlying mechanism behind DEP-
induced platelet aggregation (Alshehri et al., 2015).  
The in vivo experimental models of thrombosis primarily used to date are vascular injury 
models and ex vivo preparations which involve multifactorial thrombotic processes and do 
not distinguish specific impacts on platelets. Although DEP administered intravenously has 
been shown to increase platelet aggregation in vivo, the distinct effect on platelet aggregation 
following administration to the airways remains unclear. 
It is reported that DEP can reduce the bioavailability of nitric oxide (NO) possibly via 
uncoupling of endothelial NO synthase (eNOS) or increased oxidative stress (Knuckles, 
Lund, Lucas & Campen, 2008; Langrish et al., 2013; Wauters et al., 2013). Since NO 
generated in the vascular endothelium is a major endogenous negative regulator of platelet 
activation (Emerson, Momi, Paul, Alberti, Page & Gresele, 1999; Moore, Sanz-Rosa & 
Emerson; Moore, Tymvios & Emerson, 2010), reduced NO bioavailability following 
exposure to DEP could hypothetically lead to enhanced platelet activation.  
We hypothesised that acute exposure of the mouse airway to DEP or CB modulates platelet 
aggregation in vivo. We used an established mouse pharmacological model of radiolabelled 
platelet aggregation to explore our hypothesis and evaluated whether any observed effects on 
platelet aggregation were associated with pulmonary leukocyte infiltration, IL-6-mediated 
inflammation or related to NO activity.   
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METHODS 
Preparation of washed human platelets 
Washed platelet suspensions were prepared from citrated blood from consenting healthy 
aspirin-free male and female human donors (23 – 55 years) as previously described (Jones et 
al., 2010).  Informed consent was obtained from all donors and the procedures were approved 
by the NHS National Research Ethics Service.   
 
Light transmission aggregometry 
Human platelets were stimulated with either DEP at concentrations previously shown to 
induce concentration-dependent aggregation (12-50 g ml-1) (Solomon et al., 2013), collagen 
(5 g ml-1) or THB (HEPES-buffered Tyrode’s solution) and aggregation was measured in an 
optical aggregometer (Chrono-log Corporation, Haventown, PA, USA) for 3 min as 
previously reported (Solomon et al., 2013). The NO donor sodium nitroprusside (SNP) (10 
μM) was incubated with platelets for 5 min prior to agonist stimulation. Having consulted the 
ARRIVE guidelines (Kilkenny, Browne, Cuthill, Emerson & Altman, 2010), it was 
considered unnecessary to conduct in vitro experiments in mice on the grounds that it could 
be reasonably concluded that observations made in humans would apply to mice. Given that 
the human platelet response is the end-point of interest, in vitro experiments in mice could 
not be justified from a 3Rs perspective. 
 
Animals 
Male C57BL/6 mice (Harlan, Bicester, UK) between 20-25 g were used. eNOS knockout 
mice (eNOS
−/−
, strain 0026847) (18 – 25 g) were purchased from Jackson Laboratory (Bar 
Harbor, ME, USA) and bred in-house. Food and water were available ab libitum and animals 
were housed in groups of 5 in individually ventilated cages. Animal procedures were 
performed in accordance with our Home Office licence and with authorisation from the 
Imperial College London Ethical Review Panel. Protocols were refined in association with 
the National Centre for Replacement, Refinement and Reduction of Animals in Research 
(NC3Rs) (Tymvios, Jones, Moore, Pitchford, Page & Emerson, 2008) and are reported in 
accordance with the ARRIVE guidelines for reporting experiments involving animals 
(Kilkenny, Browne, Cuthill, Emerson & Altman, 2010). Animals were randomised to 
treatment groups. Details of anaesthesia are provided below. At the end of procedures, 
animals were killed by cervical dislocation. 
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Preparation of nanoparticles  
DEP and CB particles were prepared in sterile saline (NaCl 0.9%) or THB and sonicated 
prior to use using techniques previously described and shown to generate nanoparticulate 
suspensions (Solomon et al., 2013).    
 
Intratracheal instillation of diesel exhaust particles and carbon black 
WT and eNOS
−/−
 mice were anaesthetised with isoflourane (4 %) and a 50 µl bolus of either 
saline (0.9 % w/v), CB or DEP (25 g/mouse) was administered through a Hamilton syringe® 
attached to an oral gavage steel feeding tube. Mice were left to recover for 4 h prior to the 
experiments in a surgical recovery box.  
 
Bronchoalveolar lavage and plasma collection and cell counting 
Mice were terminally anaesthetised with urethane (10 µl g
-1
 25 % w/v i.p), bronchoalveolar 
lavage fluid (BALF) was collected as previously described (Raemdonck et al., 2016). Total 
and differential cell counts were performed as previously described (Raemdonck et al., 2016). 
Citrated blood was collected via cardiac puncture from mice terminally anesthetized with 
urethane (10 µl g
-1
 25 % w/v i.p). Blood was centrifuged at 300 rcf for 3 min and plasma 
stored at -80°C until further analysis. 
 
In vivo platelet aggregation  
A previous model of in vivo platelet aggregation was employed (Tymvios, Jones, Moore, 
Pitchford, Page & Emerson, 2008). Citrated blood was collected via cardiac puncture from 
mice (WT or eNOS
-/-
) terminally anesthetised with urethane (2g kg
-1 
i.p.). Platelets were 
isolated and radiolabelled as previously described (Tymvios, Jones, Moore, Pitchford, Page 
& Emerson, 2008). Terminally anesthetised mice (1.5 g kg
-1
 urethane i.p.) were intravenously 
(i.v.) infused with radiolabelled platelets prior to i.v. administration of collagen (50 g kg-1). 
Entrapment of platelet aggregates in the pulmonary vasculature following aggregation in the 
systemic circulation was quantified by recording changes in radioactive counts for 5 min with 
a Single Point Extended Area Ratio (SPEAR) probe (eV products, Saxonburg, PA) positioned 
over the pulmonary vasculature and custom software (Mumed systems, London, UK) as 
previously described (Tymvios, Jones, Moore, Pitchford, Page & Emerson, 2008).   
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Histological analysis of nanoparticle pulmonary deposition following intratracheal 
instillation 
Immediately following i.t. instillation mice were euthanized via cervical dislocation and their 
lungs were dissected, briefly washed in PBS and fixed in formalin overnight. Following this, 
samples were embedded in wax, sectioned (longitudinally) and stained (haematoxylin and 
eosin). The samples were viewed using a light microscope (x 20 and x 40). 
 
Enzyme-Linked Immunosorbent Assay 
WT mouse cytokines (IL-6) were quantified in cell free BALF and plasma using a standard 
sandwich ELISA (DuoSet ELISA kits, R&D Systems, USA) as per the manufacturer’s 
instructions. All samples were run in triplicate with the appropriate controls and the standard 
curve was run in duplicate. Cytokine concentrations were calculated using a standard curve.  
 
Ozone chemiluminescence for measurement of plasma nitrate 
Nitrate/nitrite concentrations were measured in plasma from mice treated with DEP or CB 
(25 g/mouse) via i.t. instillation using ozone chemiluminescence with a Sievers nitric oxide 
analyzer (280; Analytix, Boldon, UK, as previously reported (Apostoli, Solomon, 
Smallwood, Winyard & Emerson, 2014). 
 
Experimental design, data and statistical analysis  
For most protocols, blinding was not feasible as experiments were conducted by an individual 
experimentalist, however, for histological analyses, blinding was used. Unless otherwise 
stated, data is presented as box-and-whisker plots; the horizontal lines inside the box indicate 
the median. The box edges extend from the 25
th
 to the 75
th
 percentiles and the whiskers 
represent the minimum and maximum values. Statistical analyses were performed on raw 
data using Prism 5 Graphpad software. Two way analyses were conducted using a Mann-
Whitney test and multiple comparisons were conducted using a Kruskal-Wallis test with 
Dunn’s comparison. Post-hoc tests were run only if there was no significant variance in 
homogeneity. Power calculations were conducted (at level 0.8) to determine appropriate n 
numbers. A P value < 0.05 was indicative of statistical significance. Data and statistical 
analysis comply with the recommendations on experimental design and analysis in 
pharmacology (Curtis et al., 2015). 
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Materials  
Materials used were as follows: 
111
indium oxine (Mallinckrodt Radiopharmacy Services, 
London, UK); collagen (Nycomed, Munich, Germany); diesel exhaust particles (SRM 2975; 
National Institute of Standards and Technology, Gaithersburg, MD, USA); carbon black 
(Printex-90; Degussa GmbH, Hanau, Germany); cytokine ELISAs DuoSet (R&D systems, 
Minnesota, USA). All other materials were purchased from Sigma-Aldrich (Poole, UK) and 
were of analytical grade. THB contained 134 mM NaCl, 2.9 mM KCl, 12 mM NaHCO3, 0.34 
mM Na2HPO4, 20 mM HEPES, 10 mM glucose and 1 mM MgCl2 (pH 7.4). 
 
Nomenclature of targets and ligands  
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Southan et al., 2016), and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a; Alexander et al., 
2015b). 
 
RESULTS 
Diesel exhaust particles and carbon black were deposited in the conducting airways 
Since a significant proportion of PM 0.1 inhaled by humans is deposited in the distal airways 
(ICRP, 1994), the location of DEP (Fig. 1B + E) and CB (Fig 1.A + D) following i.t. 
instillation was examined. The lung microarchitecture was similar between the saline control, 
DEP and CB exposed airways (Fig. 1). Aggregates of CB and DEP were observed in contact 
with the pulmonary epithelial cells (Fig. 1E-F) and conducting airways (Fig. 1B-C). These 
data confirm that i.t. instillation of nanoparticles leads to their deposition deep in the airways. 
 
Diesel exhaust particle deposition in the airways enhanced platelet aggregation in vivo   
Having shown deposition of DEP and CB in the conducting airways, we explored whether 
this was associated acutely (4 h later) with an enhancement of agonist-induced platelet 
aggregation in vivo using a model of radiolabelled platelet thromboembolism. There was a 
significant increase in collagen-induced platelet aggregation in vivo measured as area under 
the curve (AUC) (P < 0.05 compared to saline control) 4 h following i.t. administration of 
DEP (Fig. 2A and 2C). In contrast, there was no significant enhancement of the AUC (Fig. 
2B and 2D; P > 0.05 compared to saline control) following administration of CB. 
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Carbon black exposure induced pulmonary and systemic inflammation 
Having shown contrasting impacts of DEP and CB upon in vivo platelet aggregation, we 
investigated whether these effects were associated with changes in inflammatory markers.  A 
significant increase in both neutrophils and IL-6 (P < 0.05 compared to saline; Fig. 3A+B) 
was detected in BALF following exposure to CB.  In contrast, no significant increases in 
neutrophils (Fig. 3A) or IL-6 (Fig. 3B; P > 0.05 compared to saline) were observed in BALF 
following administration of DEP. Plasma levels of IL-6 were also significantly increased 
following administration of CB but not DEP (Fig. 3C). Neither DEP nor CB caused a 
detectable change in other leukocytes in BALF (data not shown). DEP therefore enhanced in 
vivo platelet aggregation in the absence of an effect upon the inflammatory parameters 
measured whereas CB produced a detectable inflammatory response without impacting 
platelet aggregation. 
 
Diesel exhaust particles enhanced platelet aggregation in the absence of eNOS 
We explored the hypothesis that DEP exerted effects via eNOS by employing eNOS
-/-
 mice. 
A lack of effect of DEP upon platelet aggregation in eNOS
-/-
 would confirm this hypothesis. 
Following i.t. instillation of DEP into eNOS
-/- 
mice, a significant enhancement of the AUC (P 
< 0.05 compared to saline control) in response to collagen was observed after 4 h (Fig. 4A + 
B). No significant changes in AUC were detected for CB exposed eNOS 
-/-
 mice (Fig 4A + 
B). Thus, the impact of DEP upon platelet aggregation in vivo is not dependent upon the 
presence of eNOS. 
We also analysed the fold-increase in AUC following DEP or CB exposure relative to saline 
responses in order to determine whether platelet responses were proportionally different in 
eNOS
-/-
 compared to WT. Although no significant differences were observed, there was a 
non-significant trend towards an increased proportional response following DEP exposure in 
eNOS
-/-
 versus WT (Fig 4C). 
 
DEP and NO-mediated regulation of platelets     
Neither DEP nor CB instillation caused any significant alteration in plasma nitrate levels 
(Fig. 5A) indicating a lack of a detectable effect on NO bioavailability. Nitrite levels were 
below the detection limit (50 nM) of the assay. Having previously shown that DEP can 
induce platelet aggregation (Solomon et al., 2013) as well as a trend towards greater 
aggregation in the absence of eNOS (Fig. 4C), we investigated whether DEP-induced platelet 
aggregation was sensitive to the negative regulator of platelet activation, NO. Isolated human 
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platelet aggregation induced by collagen or DEP (12 – 50 µg mL-1) was significantly 
inhibited by SNP (10 µM) (P < 0.05; Fig. 5B). Typical raw data traces showing the effect of 
SNP on collagen- and DEP-induced aggregation are provided as a supplementary figure. 
Thus, we did not find evidence that the ability of DEP to enhance platelet aggregation was 
driven by changes in NO bioavailability. Under our experimental conditions in vivo, loss of 
NO did not significantly enhance aggregation, however, our in vitro data do not exclude the 
possibility that NO may inhibit the ability of DEP to directly induce platelet aggregation 
should it translocate across the epithelial barrier. 
 
DISCUSSION AND CONCLUSIONS 
In this study, we explored the hypothesis that introduction of DEP into the airways could lead 
to an enhancement of subsequent platelet aggregation in an acute time frame. One of the 
principle reasons why inhaled PM 0.1 such as DEP is considered to be responsible for the 
harmful effects of ambient PM is its deposition within the lower airways including the 
alveolar gas exchange units (ICRP, 1994). In the present study, agglomerates of DEP and CB 
were observed both in the conducting airways and the distal alveoli confirming appropriate 
lung penetration following i.t. administration. I.t. instillation therefore, to some extent, 
mimics inhalation of nanoaparticles into the airways. It is not, however, possible from the 
histological analyses conducted to observe individual nanoparticles nor to assess their 
translocation across the lung epithelium.  It is important to address the relevance of the doses 
of nanoparticles employed in this study with reference to human exposure. More than 20 mg 
of particulates can be inhaled by humans in polluted cities every 24 hours (Nemmar, Hoet, 
Dinsdale, Vermylen, Hoylaerts & Nemery, 2003). Our dosing of 25 g equates to a total 
burden of 2 mg per kg body weight so although our study was not intended to mimic human 
exposure, the levels used are probably relevant if one considers an exposure period of a few 
days. 
The thrombotic events associated with inhalation of PM 0.1 involve platelet activation and 
aggregation, however, currently there is limited information regarding the influence of DEP 
and CB on platelet function in vivo. The present study showed that DEP, but not CB, 
administered to the lungs of mice via the instillation route caused a significant increase in 
agonist-induced platelet aggregation in vivo 4 h post-exposure. These results indicate that the 
thrombotic events associated with acute pulmonary exposure to PM 0.1 may be driven 
mechanistically by platelets. 
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Supportive to the present study, acute exposure to DEP by i.t. instillation has been 
demonstrated to enhance thrombosis and platelet activation in rodent models after 30, 60 
(Nemmar, Hoet, Dinsdale, Vermylen, Hoylaerts & Nemery, 2003) or 120 min (Tabor et al., 
2016). Similarly, thrombosis was enhanced in vivo following a 24 h exposure of lungs to 
DEP (Nemmar, Al-Salam, Dhanasekaran, Sudhadevi & Ali, 2009).  Although there are 
limited clinical studies, increased thrombosis has been reported in human subjects using ex 
vivo perfusion techniques following an acute inhalation exposure (2-4 h) to DE (Lucking et 
al., 2008). In the current study, DEP has been shown to affect platelet aggregation 
independent of the other components of the thrombotic response since the model employed 
has been shown to be driven entirely by platelet aggregation in vivo (Tymvios, Jones, Moore, 
Pitchford, Page & Emerson, 2008) and in the presence of an intact endothelium (Emerson, 
2010; Tymvios, Jones, Moore, Pitchford, Page & Emerson, 2008) suggesting that DEP may 
impact platelets in the absence of endothelial dysfunction or injury. 
Inflammation is associated with increased cardiovascular risk (Mameli, Barcellona & 
Marongiu, 2009). One hypothesis regarding how PM 0.1 may promote thrombosis is 
therefore by induction of pulmonary inflammation, spill over of inflammatory cytokines into 
the systemic circulation and consequential platelet activation (Seaton, MacNee, Donaldson & 
Godden, 1995). In particular, exposure to PM has been linked with thrombotic events driven 
by IL-6 (Mutlu et al., 2007) and leukocyte influx to the airways (Nemmar, Al-Salam, 
Dhanasekaran, Sudhadevi & Ali, 2009; Nemmar, Hoet, Dinsdale, Vermylen, Hoylaerts & 
Nemery, 2003). No increases in neutrophils or IL-6 were observed following DEP exposure 
in the current study.  There was therefore no evidence of an inflammatory response to DEP in 
our model since no measured hallmarks of pulmonary inflammation were detected. This 
finding conflicts with some literature since DEP has been reported to cause increases in 
pulmonary neutrophils 1 h and 6 h following pulmonary delivery in hamsters (Nemmar, 
Hoet, Dinsdale, Vermylen, Hoylaerts & Nemery, 2003) and rats (Robertson et al., 2012). In 
contrast, other literature supports our findings by reporting dissociation of the thrombogenic 
impact of DEP from pulmonary and systemic inflammation (Tabor et al., 2016). Differences 
in the inflammatory impacts of DEP reported in various studies may be due in part to 
differences in species studied. Regardless of this, it is apparent that enhanced platelet 
activation following exposure to DEP can occur independently of quantifiable changes in the 
inflammatory response in the context of the parameters assessed in the current study. 
In terms of human studies, acute exposure to DE caused changes in thrombosis formation but 
no alterations in systemic cytokines or acute phase proteins (Lucking et al., 2011). 
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Additionally, no changes in systemic inflammatory markers were detected in healthy men 
and men with coronary artery disease exposed to DEP for 1 h with intermittent exercise 
(Mills et al., 2007; Mills et al., 2005) or 2 h after exposure to concentrated ambient particles 
(CAPs) (Mills et al., 2008). However, increases in systemic IL-6 and TNF-α 24 h following 
exposure to DEP have been reported in humans (Tornqvist et al., 2007), animals (Robertson 
et al., 2012) and at longer > 24 h time intervals (Nemmar & Inuwa, 2008). Based on the 
current data, it appears that DEP may not necessarily induce systemic inflammation 
following acute exposure and therefore may not be the underlying mechanism behind the 
enhanced platelet aggregation observed in the present work. The possibility that inflammation 
may drive platelet activation in other models and at different exposure periods cannot be 
excluded. Since nanoparticles have been suggested to translocate the lung to enter the blood 
(Kreyling et al., 2009) and DEP can directly enhance platelet activation platelets following 
physical interaction (Solomon et al., 2013), an alternative or additional hypothesised 
mechanism is translocation of DEP across the lung epithelium and subsequent exposure and 
activation of circulating platelets. The ultimate objective in proving this hypothesis would be 
visualisation of DEP in contact with activating platelets following i.t administration or 
inhalation of DEP but this has not yet been demonstrated and is technically challenging. 
In contrast to DEP, administration of CB to mice caused significant increases in neutrophils 
and IL-6 in the BALF and IL-6 in the plasma.  Systemic inflammation has similarly been 
reported following a single 7 h exposure of rats to unfractionated CB (Gilmour et al., 2004). 
The release of pro-inflammatory cytokines by CB further supports the conclusion that 
systemic inflammation was not the primary underlying mechanism behind the DEP-induced 
enhanced platelet response, as CB did not alter platelet aggregation in vivo but was associated 
with systemic inflammation. Thus, PM 0.1-associated inflammation was not linked to platelet 
aggregation in our study.  The contrasting effects of DEP and CB may suggest the 
constituents present on the surface of DEP to be responsible for the effects on platelet 
aggregation since the presence of these surface compounds and metals distinguishes the two 
pollutants. Further work to identify the biological impact of these surface components of DEP 
will provide valuable information on the mechanisms underlying the health impact of 
combustion derived air pollutants.  
A hypothesised mechanism driving DEP-enhanced platelet aggregation which was explored 
in this study was that DEP can reduce the bioavailability of endogenous NO and thereby 
reduce the inhibitory influence NO has on platelets. Acute exposure to DE has been reported 
to induce endothelial dysfunction via uncoupling of eNOS (Knuckles, Lund, Lucas & 
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Campen, 2008). DEP has also been demonstrated to enhance vasoconstriction, potentially due 
to reduced NO bioavailability (Langrish et al., 2013). If reduced NO bioavailability were 
responsible for the effects of DEP on platelet aggregation then DEP would be expected to 
have no effect on platelet aggregation in eNOS
-/-
 mice. Since DEP caused an increase in 
platelet aggregation in eNOS
-/-
 mice and did not appear to influence plasma nitrate and nitrite, 
there was no evidence of reduced NO bioavailability as an underlying mechanism driving 
increased platelet aggregation. Since NO negatively regulates platelet activation, we explored 
whether loss of eNOS in fact led to enhanced platelet aggregation. DEP had no significant 
effect on platelet aggregation in eNOS
-/-
 relative to in WT so that an effect of endogenous NO 
upon DEP-enhanced platelet aggregation could not be inferred. To explore whether, 
mechanistically, DEP-induced platelet aggregation could be impacted by NO, we conducted 
studies in vitro. DEP-induced platelet aggregation was significantly inhibited by a NO donor. 
The extent of inhibition observed was similar to that achieved with collagen and is in keeping 
with the proposed GPVI-mediated mechanism by which DEP is proposed to activate platelets 
(Alshehri et al., 2015). The finding of an inhibitory effect of NO in regulating DEP-mediated 
platelet aggregation in vitro, although not supported by the in vivo studies in this paper, is 
sufficient to hypothesise that when platelets are directly exposed to DEP, potentially 
following translocation across the lung epithelium, NO may act to oppose platelet activation. 
This suggestion is in keeping with epidemiological data which demonstrates the greatest 
cardiovascular risk in individuals with risk factors associated with endothelial dysfunction 
(Brauner et al., 2008; Brook, Brook, Urch, Vincent, Rajagopalan & Silverman, 2002; Mills et 
al., 2005; Wauters et al., 2013). Further investigation is warranted to ascertain whether NO 
acts in a physiologically cardioprotective manner to reduce DEP-driven cardiovascular risk.  
In conclusion, acute airways exposure to DEP can enhance platelet aggregation responses in 
vivo and this may provide a mechanism for the thrombotic effects which are associated with 
acute exposure to PM. Additionally, the mechanisms underlying this enhanced platelet 
response do not appear to involve the initiation of systemic inflammation or alterations in NO 
bioavailability.  Our study does, however, generate a hypothesis that healthy individuals may 
be protected from the harmful cardiovascular effects of DEP that comes into direct contact 
with platelets due to inhibition of DEP-induced platelet activation by NO. 
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Fig. 1. Deposition of diesel exhaust particles (DEP) and carbon black (CB) in mouse lungs 
following intratracheal (i.t.) instillation.  Anaesthetised WT mice were i.t. instilled with DEP 
(C + F) and CB (B + E; 25 µg/mouse) or saline (NaCl 0.9 %) (A + D). Mice were killed via 
cervical dislocation immediately after i.t. instillation and their lungs were removed and fixed 
in formalin. Samples were embedded, sectioned and stained with hematoxylin and eosin. 
Slides were visualised on a light microscope at X 20, 000 and X 40, 000. Sections from 5 
mice exposed to each treatment were observed and representative images are shown. DEP = 
diesel exhaust particles, CB = carbon black, SAL = saline.  
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 Fig. 2. Platelet aggregation in vivo following intratracheal (i.t.) instillation of diesel exhaust 
particles (DEP), carbon black (CB) or saline (SAL).  WT mice were i.t. instilled with DEP, 
CB (25 µg/mouse) or sterile saline (0.9 %). Isolated platelets were radiolabelled with 
111
indium oxine and infused into mice 4 h following i.t. instillation, prior to injection with 
collagen (50 µg kg
-1
 i.v.). Responses were recorded as changes in counts for 10 min. Platelet 
aggregation was assessed by changes in percentage maximum increase in scintillation counts 
(A+B) or area under the curve (AUC) (C+D). Data are presented as median ± interquartile 
range (A-B) or representative traces (C-D), *P < 0.05 compared using a K-W test with 
Dunn’s comparison. NS = non-significant, n = 8 (A) or 6 (B). 
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Fig. 3. Inflammatory profile in bronchoalveolar lavage fluid and plasma following 
intratracheal (i.t.) instillation of carbon black (CB), diesel exhaust particles (DEP) or saline 
(SAL). WT mice were i.t. instilled with DEP, CB (25 µg/mouse) or sterile saline (0.9 % 
NaCl). Bronchoalveolar lavage fluid (BALF) was obtained 4 h following i.t. instillation via 
catheterisation of the trachea and instillation of 400 µl of sterile saline (NaCl 0.9 %) for 30 s 
(x 3). Blood was obtained 4 h following i.t. instillation via cardiac puncture. Neutrophils (A) 
and IL-6 (B) levels were measured in the BALF and IL-6 levels were measured in the plasma 
(C). Data are presented as median and interquartile range. *P < 0.05 compared using a K-W 
test with Dunn’s comparison, n = 5 (A) or 6 (B-C).  
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Fig. 4. Platelet aggregation in vivo in eNOS 
-/- 
mice following intratracheal (i.t.) instillation of 
diesel exhaust particles (DEP), carbon black (CB) or saline (SAL).  eNOS
-/-
 mice were i.t 
instilled with DEP, CB (25 µg/mouse) or sterile saline (0.9 %). Isolated platelets were 
radiolabelled with 
111
indium oxine and infused into mice 4 h following i.t. instillation, prior 
to injection with collagen (50 µg kg
-1
). Responses were recorded for 10 min as changes in 
counts over time. Platelet aggregation was assessed by changes in percentage increase in 
scintillation counts (A) or area under the curve (AUC) (B). Fold change from the saline 
control in percentage maximum increase in scintillation counts (C) following i.t.instillation of 
DEP and CB in WT and eNOS
-/-
 mice. Data are presented as median ± interquartile range (B 
+ C) or representative traces (A). *P < 0.05 compared using a K-W test with Dunn’s 
comparison or Mann-Whitney signed rank test, n = 6 (A) or 5 (B). 
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Fig. 5. The effects of carbonaceous nanoparticles on NO bioavailability and impact of NO on 
diesel exhaust particle (DEP)-induced platelet aggregation Mice were i.t instilled with DEP, 
carbon black (CB, 25 µg/mouse) or sterile saline (SAL, 0.9 %). Blood was taken via cardiac 
puncture 4-5 h following exposure and nitrate and nitrite levels were measured in plasma 
using gas-phase chemiluminescence (nitrite levels were below the detection limit of the 
assay, 50 nM and are therefore data is presented as nitrate concentration) (A). Isolated human 
platelets were exposed to DEP (12-50 µg mL
-1
) or collagen (Coll, 5 µg mL
-1
) following a 5 
min incubation with either a NO donor sodium nitroprusside (SNP, 10 µM) or Tyrode’s 
buffer (Tyr, B). Changes in light transmission were measured for 3 min. Data are presented as 
box-and-whisker plots (A) and as median ± interquartile range (B), NS = non-significant 
compared using a K-W test with Dunn’s comparison (A),  *P < 0.05 compared against time 
matched controls using a Wilcoxon signed rank test (B). n = 6 (A) or 5 (B). 
 
